Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24289
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChristou, L.en
dc.contributor.authorHatzimichael, E. C.en
dc.contributor.authorSotsiou-Candila, F.en
dc.contributor.authorSiamopoulos, K.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:40:02Z-
dc.date.available2015-11-24T19:40:02Z-
dc.identifier.issn0001-5792-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24289-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAmyloidosis/complications/*drug therapyen
dc.subjectAntineoplastic Agents/*therapeutic useen
dc.subjectHumansen
dc.subjectImmunoglobulin Light Chains/*metabolismen
dc.subjectInterferon-alpha/*therapeutic useen
dc.subjectMaleen
dc.subjectMelphalan/therapeutic useen
dc.subjectMultiple Myeloma/complications/*drug therapy/metabolismen
dc.subjectNephrotic Syndrome/complications/*drug therapy/metabolismen
dc.subjectPrednisone/therapeutic useen
dc.subjectRemission Inductionen
dc.subjectSurvivorsen
dc.titleA patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survivalen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10436302-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000040954-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1999-
heal.abstractWe report a case of a 39-year-old man with lambda-light-chain multiple myeloma, nephrotic syndrome due to lambda-light-chain deposition disease in kidneys and amyloidosis in other tissues. The patient was treated with melphalan and prednisone for 1 year. After that, he was administered interferon-alpha2b (IFN-alpha2b; 3 MU, 3 times a week) as maintenance therapy for 2 years. At present, 5 years and 6 months after the initial diagnosis, the patient receives IFN-alpha2b (3 MU, twice a week) and remains in complete haematological remission.en
heal.journalNameActa Haematolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons